Screener
Allogene Therapeutics ALLO Business Segments — Loss before income taxes
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Allogene Therapeutics’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 4:11 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001628280-26-017242
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 |
|---|---|---|
| Facilities & IT-related spend | 28,408 | 31,727 |
| Supporting external spend | 20,698 | 27,337 |
| Other operating expenses | 53,590 | 82,989 |
| Total operating expenses | 209,315 | 273,221 |
| Other income (Expense), net | 18,429 | 16,052 |
| Loss before income taxes | (190,886) | (257,147) |
| Benefit (expense) from income taxes | — | (443) |
| Net loss | (190,886) | (257,590) |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Allogene Therapeutics's business segments — loss before income taxes?
- Allogene Therapeutics (ALLO) reported business segments — loss before income taxes of -$47.72M in Q4 2025.
- How has Allogene Therapeutics's business segments — loss before income taxes changed year-over-year?
- Allogene Therapeutics's business segments — loss before income taxes increased by 25.8% year-over-year, from -$64.29M to -$47.72M.
- What is the long-term trend for Allogene Therapeutics's business segments — loss before income taxes?
- Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — loss before income taxes has grown at a -23.6% compound annual growth rate (CAGR), from -$327.27M to -$190.89M.
- What does business segments — loss before income taxes mean?
- This metric represents the pre-tax financial performance of a specific business segment, calculated as segment revenue minus segment operating expenses. It serves as a primary indicator of the segment's operational profitability or burn rate before accounting for tax obligations. Investors use this to evaluate the economic viability and cost-efficiency of specific product lines or business units within the broader corporate structure.
Ask your AI about Allogene Therapeutics's business segments — loss before income taxes.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude